Introduction
The Human Immunodeficiency Virus (HIV) and tuberculosis (TB) syndemic continues to be a major global public health threat. In 2015, 2 billion people were living with Mycobacterium tuberculosis infection and 10.4 million developed TB disease. Of these, 1.2 million (11%) were people living with HIV (PLHIV) (1) . Of the 580,000 multi-drug resistant (MDR) tuberculosis cases, 92,000 (16%) received treatment and only 52% reported treatment success--extensively drug-resistant (XDR) TB fared worse, reporting a 28% treatment success rate in 2013 (1) . Many of these deadly, airborne, TB cases occur among highly vulnerable PLHIV who, without HIV treatment, have a 10% risk of developing TB per year (2) . Antiretroviral treatment (ART) reduces the individual risk of TB by approximately 65% (3) , and by 90% when coupled with isoniazid preventive therapy (IPT) (4, 5) . However, by mid-2016, only 18.2 million (50%) of PLHIV were on HIV treatment and most were not offered IPT (6) . Additionally, HIV-associated TB is curable with early treatment for TB and HIV (7, 8) . However, 2015 global TB case detection was only 59% (1) . Although there has been impressive improvements in both HIV and TB treatment coverage, the gap contributed to millions of new TB infections, 1.4 million TB deaths (in HIV-negative), 2.1 million HIV infections, 1.1 million HIV-associated deaths, and 1.2 million HIV-associated TB cases and 390,000 HIV-associated TB deaths (1, 6) .
Each new HIV-associated TB case among people who are not on ART is a missed public health opportunity or failure. To prevent HIV and TB illness, death and transmission, the Joint United Nations Program on HIV/AIDS (UNAIDS) proposed the 90-90-90 target by 2020 to end AIDS (9)--diagnose 90% of people living with HIV, provide ART for 90% of people diagnosed, and 90% of people on ART with viral suppression. The target will be attained when at least 29.5 (73%) million PLHIV are on ART and virally suppressed (17 million in sub-Saharan Africa alone) (9) . The 90-90-90 target envisions 27% of PLHIV unsuppressed which is further reduced to 14% unsuppressed for the 2030 target of 95-95-95 (9) . For ending TB, the Stop TB Partnership has issued a Global Plan with 2035 targets including a 95% reduction in deaths, 90% reduction in TB incidence to 10/100,000 population, and zero families facing catastrophic TB costs (10). Similarly, the Sustainable Development Goals target a 90% reduction in TB deaths and 80% reduction in incidence by 2030 (11). The World Health Organization (WHO) issued The End TB strategy with similar 2035 targets as the Partnership Plan and adds 2025 targets of 90% treatment coverage, 90% treatment success, 90% prevention coverage, and 90% new drugs uptake (10, 12). Achieving the global HIV and TB targets will have a major impact on both epidemics, however, the lack of a comprehensive integrated disease control strategy jeopardizes success for either individual disease effort. In this paper we examine global HIV and TB policy, HIV and TB disease control budgets, and a new combined TB and HIV care continua.
HIV and TB Policy
In 2004, WHO released guidance on TB-HIV collaborative activities and in 2007 introduced the Three I's for TB/HIV (intensified TB case finding, IPT and infection control) (13-15). Although most high burden countries have adopted the Three I's for HIV/TB, availability of IPT and infection control is limited in most settings (16, 17) . HIV is the strongest risk factor for TB, ART and IPT together can reduce TB by nearly 90%, and multiple studies have found that providing early ART for people diagnosed with TB disease can reduce mortality by 50% (4, 7, The new science and improved policies has supported remarkable progress over the last decade with an estimated 43 million lives saved, 47% reduction in TB mortality due to TB treatment, and a 32% reduction in HIV-associated TB deaths with the additional benefit of preventing millions of HIV and TB illnesses, deaths and new infections between 1996 and 2014 (1, 6, 20, 21) . However, implementation of many TB and HIV policy recommendations is incomplete (16, 17, 22) -in 2015 TB killed one out of three PLHIV globally and it remains the leading cause of morbidity and mortality among PLHIV (1).
Global investment in HIV and TB control
The goal of controlling the HIV epidemic is now within reach. The President Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund (GF) have focused efforts on jointly addressing HIV-associated TB through HIV and TB single concept notes and promoting joint TB and HIV programming (Table 1) (32), however, early diagnosis and combined HIV and TB treatment can reduce mortality by 50% (7, 8) . Global TB treatment success in 2014 was 83%, however, it is 75% for PLHIV (1) . Reasons for the poorer outcomes include late access to HIV testing and treatment since most countries, until recently, were following WHO recommendations to wait for severe immune degradation before starting HIV treatment (16) . An integrated approach to improving earlier HIV testing and TB case detection can synergize and amplify efforts to reach 90-90-90 and TB control targets.
Undiagnosed and untreated TB causes viral replication directly compromising the 90-90-90 durable viral suppression target (33) . Routine TB control activities including case finding, provision of treatment or IPT as needed, and TB infection control all contribute to achieving viral load suppression. Integration of TB diagnosis and HIV viral load measurement using a common laboratory platform has significant promise if its costs can be reduced. Achieving both the 90-90-90 HIV target and global TB strategy goals (9-12) are critical to prevent millions of preventable TB and HIV illnesses, deaths and new infections.
Monitoring and evaluating for "one patient two diseases"
Despite the fact that in many high burden settings up to 71% of people with active TB are co- 
"What is not measured is not done": combined HIV and TB control care continua
Starting immediate ART irrespective of CD4 cell count can reduce HIV-related morbidity, mortality, transmission and costs (5, 20, 35, 36) . However, to realize the benefits PLHIV must optimally engage at each step along the 'HIV care continua' (referred to as continua hereafter) (37, 38) , from early HIV diagnosis to access to ART and viral suppression. HIV care continua have become vital tools to monitor the HIV programmatic efforts and guide actions to achieve 90-90-90-90 (9, 38). As of 2015, only 60% of PLHIV globally had been diagnosed, 46% were reported on ART and 38% PLHIV were estimated to be virally suppressed (39). From the TB care continuum perspective, global TB case detection was only 59%, treatment success was 83%, and only 42% of the estimated people living with HIV and TB were reported to be on dual 
Comprehensive HIV and TB continua data
Data for a combined HIV and TB continua are available in the public domain, however, they are often fragmented, from different sources, focused on HIV or TB only, and not aggregated into a comprehensive HIV and TB continua. We used data from the HIV90-90-90watch website (38, 40), UNAIDS Aidsinfo, and the WHO 2016 Global TB Report (1) for the 22 WHO high TB and TB/HIV burden priority countries (81% HIV/TB burden) to determine the feasibility of constructing comprehensive HIV and TB continua ( Table 2 ). The combined continuum (constructed for South Africa and India) includes new combined integrated indicators that capture PLHIV receiving ART and TB prevention interventions and those with TB who have received successful TB treatment and viral suppression (Figures 2 and 3) . These composite indicators further emphasize an integrated approach to HIV and TB control. Viral load data was not available for 13 countries and none of the countries included information regarding the combined indicators: TB treatment success and viral suppression among HIV/TB or TB prevention and ART for PLHIV. PLHIV on ART ranged from 9-70% and TB treatment coverage was between 15-87% (Figure 4 ). Viral suppression of PLHIV ranged from 38-63% [79-90% among PLHIV on ART] while TB treatment success ranged from 34-94% ( Figure 5 , Table   2 ). Only 3% of PLHIV in the 22 countries reported course of IPT. Although the TB monitoring and evaluation system with its reliance on quarterly cohorts is over 40 years old, the HIV care continuum is a relatively new concept (37) and many countries are still struggling to measure continua and the 90-90-90 target (38) . For example, only a few countries could produce national cohorts and/or national program data that include HIV diagnosis through viral suppression (38) . In contrast toTB cohort analyses based on following individual patients over time, most countries derive indirect ross-sectional estimates of HIV continua numerators, which may be prone to data errors and methodological flaws. Specifically, without patient identifiers and a cohort system, patient loss after diagnosis, duplication of patients in the system, and lack of individually linked viral load results may compromise the validity of some continua. Also, this study did not evaluate the availability of high burden subnational or population-specific care continuums (e.g., key populations) for HIV or TB, which may more directly inform strategies for targeted program improvement and community incidence interruption.
Conclusion
The adoption of the 90-90-90 target has significant promise for ending the HIV epidemic.
Focusing on diagnosing and ensuring that PLHIV access earlier ART also makes sense from a TB control perspective since it is also proven to prevent HIV-associated TB disease, deaths, and transmission. Likewise, diagnosing and treating active TB can be life-saving, prevents transmission and, for PLHIV, allows for achieving HIV viral suppression. Given the significant interaction between the two pathogens, combining disease control objectives to achieve HIV 90-90-90, end of AIDS, and the TB 90-90-90 targets makes sense. In geographic settings and populations with high TB and HIV burdens, changing health services so that they can deliver a comprehensive combined TB and HIV continuum of care will be essential to achieving the 90-90-90 and TB control targets. Simplifying and combining the existing multiple, separate disease control strategies, reducing inefficient, duplicative siloed funding and programming, and combining and simplifying monitoring and evaluation of service delivery and impact are essential given current resource constraints. The goal of both HIV and TB programs, to control and eliminate both diseases, can only be accomplished when both TB and HIV targets are achieved. Using a comprehensive HIV and TB care continuum provides an opportunity to harness both the HIV and TB response to improve the health of people infected with HIV and/or M. tuberculosis infection, diagnosed with TB disease, their families and the community. 
